Clinical Trial Update: Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

View source ↗

Summary

This Clinical Trial Update reports results from a Special Drug Use Surveillance study of Brentuximab Vedotin IV in relapsed or refractory CD30-positive peripher…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma | Status: COMPLETED | Results posted: 2024-09-27